HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gough, M. Articles by Vile, R. Search for Related Content PubMed PubMed Citation Articles by Gough, M. Articles by Vile, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Genes and Gene Therapy

Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy ¹

Michael Gough^2,*,, Marka Crittenden^*,, Uma Thanarajasingam^*,, Luis Sanchez-Perez^*,, Jill Thompson^*, Dragan Jevremovic^*, and Richard Vile^*,

^* Molecular Medicine Program and Departments of Immunology and Pathology, Mayo Clinic, Rochester, MN 55905

Strategies that generate tumor Ag-specific effector cells do not necessarily cure established tumors. We hypothesized that the relative efficiency with which tumor-specific effector cells reach the tumor is critical for therapy. We demonstrate in this study that activated T cells respond to the chemokine CCL3, both in vitro and in vivo, and we further demonstrate that expression of CCL3 within tumors increases the effector T cell infiltrate in those tumors. Importantly, we show that adenoviral gene transfer to cause expression of CCL3 within B16ova tumors in vivo increases the efficacy of adoptive transfer of tumor-specific effector OT1 T cells. We additionally demonstrate that such therapies result in endogenous immune responses to tumor Ags that are capable of protecting animals against subsequent tumor challenge. Strategies that modify the "visibility" of tumors have the potential to significantly enhance the efficacy of both vaccine and adoptive transfer therapies currently in development.

This article has been cited by other articles:

				M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor Cancer Res., July 1, 2008; 68(13): 5206 - 5215. [Abstract] [Full Text] [PDF]

				E. Cittera, M. Leidi, C. Buracchi, F. Pasqualini, S. Sozzani, A. Vecchi, J. D. Waterfield, M. Introna, and J. Golay The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab J. Immunol., May 15, 2007; 178(10): 6616 - 6623. [Abstract] [Full Text] [PDF]

				Y. Tang, H. Akbulut, J. Maynard, L. Petersen, X. Fang, W.-W. Zhang, X. Xia, J. Koziol, P.-J. Linton, and A. Deisseroth Vector Prime/Protein Boost Vaccine That Overcomes Defects Acquired during Aging and Cancer J. Immunol., October 15, 2006; 177(8): 5697 - 5707. [Abstract] [Full Text] [PDF]

				F. Vianello, N. Papeta, T. Chen, P. Kraft, N. White, W. K. Hart, M. F. Kircher, E. Swart, S. Rhee, G. Palu, et al. Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control. J. Immunol., March 1, 2006; 176(5): 2902 - 2914. [Abstract] [Full Text] [PDF]